Abstract: Methods for prophylactic treatment of hemophilia B are provided in which modified FIX polypeptides, particularly FIXa, are subcutaneously administered daily or less frequently, such as every other day, or every 2, 3 or 4 days. The treatment results in normal coagulation pharmacokinetics and normal levels of FIX, or mild hemophilia B.

Abstract: Provided herein are modified FVII polypetides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.

Abstract: An approach is provided in which a system writes a set of data into a register file entry that includes a first memory array and a second memory array. The register file entry also includes a set of first write ports corresponding to the first memory array and a set of second write ports corresponding to the second memory array. The system configures a selection bit based on determining that a selected one of the set of first write ports is utilized to store the set of data in the first memory array. In turn, the system reads the set of data out of the first memory array based on the configured selection bit.

Abstract: Provided herein are modified FVII polypetides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.

Abstract: Provided herein are modified FVII polypeptides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.

Abstract: An approach is provided in which a system writes a set of data into a register file entry that includes a first memory array and a second memory array. The register file entry also includes a set of first write ports corresponding to the first memory array and a set of second write ports corresponding to the second memory array. The system configures a selection bit based on determining that a selected one of the set of first write ports is utilized to store the set of data in the first memory array. In turn, the system reads the set of data out of the first memory array based on the configured selection bit.

Abstract: A circuit has been developed that reduces the effective strength of a keeper circuit during an interval in which at least one path of an evaluation circuit is sensitive to a keeper device. The keeper circuit includes a keeper gating device coupled to a keeper device that is responsive to a keeper control. The keeper device is sized to overcome leakage current in the evaluation circuit. In some configurations, the keeper circuit includes a weak keeper device that is minimally sized to overcome noise while the keeper device is effectively disabled. In some configurations, the reduction in effective strength of the keeper circuit occurs before arrival of the fastest signal coupled to a sensitive output path of the evaluation circuit and the effective strength is restored after arrival of the slowest signal coupled to the sensitive output path of the evaluation circuit.

Abstract: A circuit has been developed that reduces the effective strength of a keeper circuit during an interval in which at least one path of an evaluation circuit is sensitive to a keeper device. The keeper circuit includes a keeper gating device coupled to a keeper device that is responsive to a keeper control. The keeper device is sized to overcome leakage current in the evaluation circuit. In some configurations, the keeper circuit includes a weak keeper device that is minimally sized to overcome noise while the keeper device is effectively disabled. In some configurations, the reduction in effective strength of the keeper circuit occurs before arrival of the fastest signal coupled to a sensitive output path of the evaluation circuit and the effective strength is restored after arrival of the slowest signal coupled to the sensitive output path of the evaluation circuit.

Abstract: A timing model is constructed using a timing view of a functional component of a circuit under consideration. This timing view uses one or more timing elements to replace timing determinant blocks of the actual circuitry for the purposes of timing analysis. These timing elements represent signal delays from point to point in the circuit and relative timing between signals in the circuit, and thus represent the important timing characteristics of the actual circuitry. After creating the timing view of the circuit, a cross-section of the circuit comprising the functional component is simulated to produce values for delays and relative timing between signals in the circuit. These values from the circuit simulation are then attached to the various timing elements in the timing view to create the timing model for the portion of the circuit represented by the timing view.

Abstract: Disclosed is a lavage valve apparatus and a method of using the valve. The valve comprises a valve body having three apertures and a bypass passageway. A movable valve member with truncated end portions moves linearly within the valve body by means of hydraulic pressure or mechanical (or magnetic) bias. Application of hydraulic pressure via a syringe pumps irrigation fluid through the valve into the patient. Termination of hydraulic pressure allows mechanical re-seating of the movable valve member and vacuum withdrawal of the fluid.